REPL Replimune Group Inc

Price (delayed)

$9.88

Market cap

$815.82M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$3.44

Enterprise value

$767.51M

Relative Growth: Rel. Growth:
Relative Strength: Rel. Strength:
Relative Valuation: Rel. Valuation:
Relative Profitability: Rel. Profitability: 3

Replimune Group, Inc., headquartered in Woburn, MA, was founded in 2015 to develop the next generation of oncolytic immune-gene therapies for the treatment of cancer. Replimune is developing novel, proprietary ...

Highlights
The company's equity has shrunk by 56% YoY and by 20% QoQ
Replimune Group's quick ratio has plunged by 52% YoY and by 12% from the previous quarter

Key stats

What are the main financial stats of REPL

REPL stock price

How has the Replimune Group stock price performed over time
Intraday
-1%
1 week
111.11%
1 month
226.07%
1 year
1.96%
YTD
1.65%
QTD
29.15%

Financial performance

How have Replimune Group's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$325.91M
Net income
-$314.85M
Gross margin
N/A
Net margin
N/A
The net income has contracted by 38% YoY
The operating income has declined by 35% year-on-year

Price vs fundamentals

How does REPL's price correlate with its fundamentals

Growth

What is Replimune Group's growth rate over time

Valuation

What is Replimune Group stock price valuation
P/E
N/A
P/B
3.68
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The company's EPS fell by 12% YoY
REPL's price to book (P/B) is 69% higher than its 5-year quarterly average of 2.2 and 69% higher than its last 4 quarters average of 2.2
The company's equity has shrunk by 56% YoY and by 20% QoQ

Efficiency

How efficient is Replimune Group business performance
REPL's ROE has shrunk by 87% YoY and by 24% QoQ
Replimune Group's return on invested capital has shrunk by 76% YoY and by 18% QoQ
Replimune Group's return on assets has shrunk by 68% YoY and by 17% QoQ

Dividends

What is REPL's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for REPL.

Financial health

How did Replimune Group financials performed over time
The total assets is 171% more than the total liabilities
Replimune Group's quick ratio has plunged by 52% YoY and by 12% from the previous quarter
REPL's current ratio has shrunk by 51% YoY and by 11% QoQ
Replimune Group's debt is 64% less than its equity
The debt to equity has surged by 125% year-on-year and by 24% since the previous quarter
The company's equity has shrunk by 56% YoY and by 20% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.